Pharmaceutical composition comprising substance inhibiting enzymatic activity of peroxiredoxin 2 as effective ingredient for treatment of colorectal cancer
AssigneeEwha University-Industry Collaboration Foundation
InventorSang Won Kang
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition for treating colorectal cancer including a material inhibiting the enzyme activity of peroxiredoxin 2 as an active ingredient, and more specifically, to a pharmaceutical composition for treating colorectal cancer, which exhibits the effect of reducing colon polyps via increase of active β-catenin degradation by inhibiting the activity of peroxiredoxin 2, based on the mechanism that promotes colorectal tumor by the interaction between peroxiredoxin 2 (PrxII) and tankyrase (TNKS) in an APC-mutant cell.
Claims7
A method for improving or treating colorectal cancer in a subject in need thereof, comprising the step of administering a pharmaceutically effective dose of a material inhibiting an enzyme activity of peroxiredoxin 2 to the subject,
- wherein the material inhibiting the enzyme activity of peroxiredoxin 2 is a compound of the following Formula 1:
- wherein in Formula 1 above,
- R1 is —O—R2, a cyclic group, or hydrogen;
- and
- R2 is a branched or unbranched C1 to C8 alkyl, a branched or unbranched C2 to C8 alkenyl, a branched or unbranched C2 to C8 alkynyl, or an aromatic or non-aromatic cyclic group that is substituted or unsubstituted.
Dependencies are inferred from the claim text.